Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated January 16, 2019, serves as an Extraordinary Report submitted to the U.S. Securities and Exchange Commission. The report details a corporate resolution to liquidate two specified subsidiaries: Takeda Europe Holdings B.V. (Netherlands) and Takeda A/S (Denmark).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes regarding subsidiary liquidation.
- Takeda Europe Holdings B.V. Capital: EUR 280 million
- Takeda A/S Capital: EUR 134 thousand
Material Changes
The primary material change reported is the decision to liquidate the two specified subsidiaries, resulting in the following changes to voting rights ownership:
- Takeda Europe Holdings B.V.: Ownership decreased from 100% (2,801,795 votes) to 0%.
- Takeda A/S: Ownership decreased from 100% (13,362,814 votes, including 23.9% indirect ownership) to 0%.
Both entities previously held shares of Takeda group entities in Europe.
Outlook, Risks, and Management Commentary
Management has initiated the administrative processes for liquidation in compliance with local regulations. However, the filing explicitly states that the date of completion for the liquidation cannot be determined yet. No specific financial risks, contingencies, or unusual items related to the liquidation were disclosed in this text.
Investor Verification Checklist
- Verify the timeline for the completion of the liquidation processes for Takeda Europe Holdings B.V. and Takeda A/S.
- Confirm the impact of these liquidations on the consolidated financial statements and any potential asset write-downs or restructuring costs.
- Review subsequent filings for updates on the administrative progress and final closure dates.